Mouse Anti-HPGD Recombinant Antibody (CBFYH-1884) (CBMAB-H2892-FY)

Name: Mouse Anti-HPGD Recombinant Antibody (CBFYH-1884)
SKU: CBMAB-H2892-FY
Rating: 5 (1 reviews)

See all HPGD antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CBFYH-1884

Application

WB, IHC, FC

Immunogen

Full length human recombinant protein of human HPGD produced in HEK293T cell

Specificity

Human

Antibody Isotype

IgG1

Clonality

Monoclonal

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS, PH 7.3, 1% BSA, 50% glycerol

Preservative

0.02% Sodium azide

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

hydroxyprostaglandin dehydrogenase 15-(NAD)

Introduction

This gene encodes a member of the short-chain nonmetalloenzyme alcohol dehydrogenase protein family. The encoded enzyme is responsible for the metabolism of prostaglandins, which function in a variety of physiologic and cellular processes such as inflammation. Mutations in this gene result in primary autosomal recessive hypertrophic osteoarthropathy and cranioosteoarthropathy. Multiple transcript variants encoding different isoforms have been found for this gene.

Entrez Gene ID

3248

UniProt ID

P15428

Alternative Names

15-Hydroxyprostaglandin Dehydrogenase; Short Chain Dehydrogenase/Reductase Family 36C Member 1; 15-Hydroxyprostaglandin Dehydrogenase (NAD(+)); Hydroxyprostaglandin Dehydrogenase 15-(NAD); Prostaglandin Dehydrogenase 1; EC 1.1.1.141; 15-PGDH; SDR36C1

Function

Catalyzes the NAD-dependent dehydrogenation (oxidation) of a broad array of hydroxylated polyunsaturated fatty acids (mainly eicosanoids and docosanoids, including prostaglandins, lipoxins and resolvins), yielding their corresponding keto (oxo) metabolites (PubMed:8086429, PubMed:10837478, PubMed:16828555, PubMed:16757471, PubMed:21916491, PubMed:25586183).

Decreases the levels of the pro-proliferative prostaglandins such as prostaglandin E2 (whose activity is increased in cancer because of an increase in the expression of cyclooxygenase 2) and generates oxo-fatty acid products that can profoundly influence cell function by abrogating proinflammatory cytokine expression (PubMed:25586183, PubMed:15574495).

Converts resolvins E1, D1 and D2 to their oxo products, which represents a mode of resolvin inactivation. Resolvin E1 plays important roles during the resolution phase of acute inflammation, while resolvins D1 and D2 have a unique role in obesity-induced adipose inflammation (PubMed:16757471, PubMed:22844113).

Biological Process

Ductus arteriosus closure Source: UniProtKB
Female pregnancy Source: UniProtKB
Kidney development Source: Ensembl
Lipoxygenase pathway Source: UniProtKB
Negative regulation of cell cycle Source: UniProtKB
Ovulation Source: UniProtKB
Parturition Source: UniProtKB
Positive regulation of apoptotic process Source: Ensembl
Positive regulation of vascular associated smooth muscle cell proliferation Source: Ensembl
Prostaglandin metabolic process Source: UniProtKB
Regulation of prostaglandin catabolic process Source: UniProtKB
Response to estradiol Source: Ensembl
Response to ethanol Source: Ensembl
Response to lipopolysaccharide Source: Ensembl
Thrombin-activated receptor signaling pathway Source: UniProtKB
Transforming growth factor beta receptor signaling pathway Source: UniProtKB

Cellular Location

Cytoplasm

Involvement in disease

Hypertrophic osteoarthropathy, primary, autosomal recessive, 1 (PHOAR1):
A disease characterized by digital clubbing, periostosis, acroosteolysis, painful joint enlargement, and variable features of pachydermia that include thickened facial skin and a thickened scalp. Other developmental anomalies include delayed closure of the cranial sutures and congenital heart disease.
Cranioosteoarthropathy (COA):
A form of osteoarthropathy characterized by swelling of the joints, digital clubbing, hyperhidrosis, delayed closure of the fontanels, periostosis, and variable patent ductus arteriosus. Pachydermia is not a prominent feature.
Digital clubbing, isolated congenital (DIGC):
A rare genodermatosis characterized by enlargement of the nail plate and terminal segments of the fingers and toes, resulting from proliferation of the connective tissues between the nail matrix and the distal phalanx. It is usually symmetrical and bilateral (in some cases unilateral). In nail clubbing usually the distal end of the nail matrix is relatively high compared to the proximal end, while the nail plate is complete but its dimensions and diameter more or less vary in comparison to normal. There may be different fingers and toes involved to varying degrees. Some fingers or toes are spared, but the thumbs are almost always involved.

de Assis, V., Guzeloglu-Kayisli, O., Ozmen, A., Semerci-Gunay, N., Hasan, A. H., Lockwood, C., & Kayisli, U. (2023). 15-Hydroxyprostaglandin dehydrogenase: the samurai of trophoblasts induces uterine quiescence through decidual interactions. American Journal of Obstetrics & Gynecology, 228(1), S583-S584.

Volpato, M., Cummings, M., Shaaban, A. M., Abderrahman, B., Hull, M. A., Maximov, P. Y., ... & Speirs, V. (2020). Downregulation of 15-hydroxyprostaglandin dehydrogenase during acquired tamoxifen resistance and association with poor prognosis in ERα-positive breast cancer. Exploration of targeted anti-tumor therapy, 1, 355.

Satapathy, S. R., Topi, G., Osman, J., Hellman, K., Ek, F., Olsson, R., ... & Sjölander, A. (2020). Tumour suppressor 15-hydroxyprostaglandin dehydrogenase induces differentiation in colon cancer via GLI1 inhibition. Oncogenesis, 9(8), 74.

Monteleone, N. J., Moore, A. E., Iacona, J. R., Lutz, C. S., & Dixon, D. A. (2019). miR-21-mediated regulation of 15-hydroxyprostaglandin dehydrogenase in colon cancer. Scientific reports, 9(1), 5405.

Roizen, J. D., Asada, M., Tong, M., Tai, H. H., & Muglia, L. J. (2019). Early pregnancy loss in 15-hydroxyprostaglandin dehydrogenase knockout (15-HPGD−/−) mice due to requirement for embryo 15-HPGD activity. Scientific Reports, 9(1), 17612.

Zhai, Y., Bai, J., Wang, S., Li, M., Wang, F., Li, C., & Zhang, Y. (2018). Aberrant expression of extracellular signal-regulated kinase and 15-hydroxyprostaglandin dehydrogenase indicates radiation resistance and poor prognosis for patients with clival chordomas. World Neurosurgery, 115, e146-e151.

Arima, K., Komohara, Y., Bu, L., Tsukamoto, M., Itoyama, R., Miyake, K., ... & Ishimoto, T. (2018). Downregulation of 15‐hydroxyprostaglandin dehydrogenase by interleukin‐1β from activated macrophages leads to poor prognosis in pancreatic cancer. Cancer Science, 109(2), 462-470.

Wang, W., Hu, Y., Wang, X., Wang, Q., & Deng, H. (2018). ROS-Mediated 15-Hydroxyprostaglandin dehydrogenase degradation via cysteine oxidation promotes NAD+-Mediated Epithelial-Mesenchymal Transition. Cell Chemical Biology, 25(3), 255-261.

Park, Y. S., Lee, J. H., Jung, D. B., Kim, H. B., Jung, J. H., Pak, S., ... & Myung, S. J. (2018). MicroRNA-21 induces loss of 15-hydroxyprostaglandin dehydrogenase in early gastric tubular adenocarcinoma. Scientific Reports, 8(1), 17717.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-HPGD Recombinant Antibody (CBFYH-1884)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme-Linked Immunospot (ELISpot)
Proteogenomics
Other Protocols

Related Products

Rabbit Anti-HPGD Recombinant Antibody (CBFYH-1888) (CAT#: CBMAB-H2894-FY)

Mouse Anti-HPGD Recombinant Antibody (CBFYH-1893) (CAT#: CBMAB-H2899-FY)

Rabbit Anti-HPGD (AA 1-266) Recombinant Antibody (CBFYH-1890) (CAT#: CBMAB-H2896-FY)

Mouse Anti-HPGD Monoclonal Antibody (CBFYH-3197) (CAT#: CBMAB-H2891-FY)

Rabbit Anti-HPGD Recombinant Antibody (CBFYH-1886) (CAT#: CBMAB-H2893-FY)

Mouse Anti-HPGD (AA 1-266) Recombinant Antibody (CBFYH-1891) (CAT#: CBMAB-H2897-FY)

Rabbit Anti-HPGD Recombinant Antibody (CBFYH-1885) (CAT#: CBMAB-H0008-FY)

Mouse Anti-HPGD Recombinant Antibody (1C12) (CAT#: CBMAB-1270-LY)

Mouse Anti-HPGD Recombinant Antibody (1D8) (CAT#: CBMAB-1271-LY)

Mouse Anti-HPGD Recombinant Antibody (1C10) (CAT#: CBMAB-1269-LY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry